Abstract
Perfluorocarbons (PFCs) are fluorinated compounds that have been used for many years in clinics mainly as gas/oxygen carriers and for liquid ventilation. Besides this main application, PFCs have also been tested as contrast agents for ultrasonography and magnetic resonance imaging since the end of the 1970s. However, most of the PFCs applied as contrast agents for imaging were gaseous. This class of PFCs has been recently substituted by liquid PFCs as ultrasound contrast agents. Additionally, liquid PFCs are being tested as contrast agents for 19F magnetic resonance imaging (MRI), to yield dual contrast agents for both ultrasonography and 19F MRI. This review focuses on the development and applications of the different contrast agents containing liquid perfluorocarbons for ultrasonography and/or MRI: large and small size emulsions (i.e. nanoemulsions) and nanocapsules.
Similar content being viewed by others
Abbreviations
- FDA:
-
food and drug administration
- GI:
-
gastrointestinal
- i.v.:
-
intravenous
- MR:
-
magnetic resonance
- MRI:
-
magnetic resonance imaging
- MRS:
-
magnetic resonance spectroscopy
- PEG:
-
polyethylene glycol
- PEG-PCL:
-
PEG-block-poly(caprolactone)
- PEG-PLLA:
-
poly(ethylene glycol)-block-poly(L-lactide)
- PFCs:
-
perfluorocarbons
- PFD:
-
perfluorodecalin
- PFH:
-
perfluorohexane
- PFN:
-
perfluorononane
- PFOB:
-
perfluorooctylbromide
- PFP:
-
perfluoropentane
- PLGA:
-
poly(lactide-co-glycolide)
- SNR:
-
signal-to-noise ratio
- THI:
-
tissue harmonic imaging
- UCAs:
-
ultrasound contrast agents
- US:
-
ultrasound
References
Riess JG. Blood substitutes and other potential biomedical applications of fluorinated colloids. J Fluorine Chem. 2002;114:119–26.
Gross U, Rudiger S, Reichelt H. Perfluorocarbons—chemically inert but biologically-active. J Fluorine Chem. 1991;53:155–61.
Lehmler HJ, Bummer PM, Jay M. Liquid ventilation—a new way to deliver drugs to diseased lungs? Chemtech. 1999;29:7–12.
Liuand MS, Long DM. Perfluoroctylbromide as a diagnostic contrast medium in gastroenterography. Radiology. 1977;122:71–6.
Lowe KC. Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev. 1999;13:171–84.
Leese PT, Noveck RJ, Shorr JS, Woods CM, Flaim KE, Keipert PE. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesth Analg. 2000;91:804–11.
Noveck RJ, Shannon EJ, Leese PT, Shorr JS, Flaim KE, Keipert PE, et al. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg. 2000;91:812–22.
Spahn DR. Blood substitutes artificial oxygen carriers: perfluorocarbon emulsions. Crit Care. 1999;3:R93–7.
Lowe KC. Engineering blood: synthetic substitutes from fluorinated compounds. Tissue Eng. 2003;9:389–99.
Gross GW, Greenspan JS, Fox WW, Rubenstein SD, Wolfson MR, Shaffer TH. Use of liquid ventilation with perflubron during extracorporeal membrane-oxygenation—chest radiographic appearances. Radiology. 1995;194:717–20.
Lozano JA, Castro JA, Rodrigo I. Partial liquid ventilation with perfluorocarbons for treatment of ARDS in burns. Burns. 2001;27:635–42.
Hamon I. Liquid ventilation: a new mode of ventilation in neonatology? Arch Pediatr. 1997;4:176–80.
Mattrey RF, Long DM, Multer F, Mitten R, Higgins CB. Perfluoroctylbromide: a reticuloendothelial-specific and tumor-imaging agent for computed tomography. Radiology. 1982;145:755–8.
Young SW, Enzmann DR, Long DM, Muller HH. Perfluoroctylbromide contrast enhancement of malignant neoplasms: preliminary observations. AJR Am J Roentgenol. 1981;137:141–6.
Klibanov AL. Ultrasound molecular imaging with targeted microbubble contrast agents. J Nucl Cardiol. 2007;14:876–84.
Mattrey RF. The potential role of perfluorochemicals (PFCs) in diagnostic imaging. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:295–313.
Schutt EG, Klein DH, Mattrey RM, Riess JG. Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals. Angew Chem Int Edit. 2003;42:3218–35.
Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J Control Release. 2006;114:89–99.
Dijkmans PA, Juffermans LJ, Musters RJ, van Wamel A, ten Cate FJ, van Gilst W, et al. Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr. 2004;5:245–56.
Lanzaand GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Probl Cardiol. 2003;28:625–53.
Hernotand S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev. 2008;60:1153–66.
Oeffinger BE, Wheatley MA. Development and characterization of a nano-scale contrast agent. Ultrasonics. 2004;42:343–7.
Sontum PC. Physicochemical characteristics of Sonazoid (TM), a new contrast agent for ultrasound imaging. Ultrasound Med Biol. 2008;34:824–33.
Goldberg B. Ultrasound contrast agents. London: Dunitz; 2001.
Lindner JR. Microbubbles in medical imaging: current applications and future directions. Nat Rev Drug Discov. 2004;3:527–33.
Calliada F, Campani R, Bottinelli O, Bozzini A, Sommaruga MG. Ultrasound contrast agents: basic principles. Eur J Radiol. 1998;27(Suppl 2):S157–60.
Grant EG. Sonographic contrast agents in vascular imaging. Seminars in Ultrasound Ct and Mri. 2001;22:25–41.
Ngo FC, Hall CS, Marsh JN, Fuhrhop RW, Allen JS, Brown P, et al. Evaluation of liquid perfluorocarbon nanoparticles as a blood pool contrast agent utilizing power Doppler harmonic imaging. 2000 Ieee Ultrasonics Symposium Proceedings. 2000;1 and 2:1931–4.
Wickline SA, Hughes M, Ngo FC, Hall CS, Marsh JN, Brown PA, et al. Blood contrast enhancement with a novel, non-gaseous nanoparticle contrast agent. Acad Radiol. 2002;9:S290–3.
Bokor D. Diagnostic efficacy of SonoVue. Am J Cardiol. 2000;86:19G–24.
Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86:669–74.
Lindner JR, Song J, Jayaweera AR, Sklenar J, Kaul S. Microvascular rheology of Definity microbubbles after intra-arterial and intravenous administration. J Am Soc Echocardiogr. 2002;15:396–403.
Cohen JL, Cheirif J, Segar DS, Gillam LD, Gottdiener JS, Hausnerova E, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. J Am Coll Cardiol. 1998;32:746–52.
Correas JM, Bridal L, Lesavre A, Mejean A, Claudon M, Helenon O. Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur Radiol. 2001;11:1316–28.
Straub JA, Chickering DE, Church CC, Shah B, Hanlon T, Bernstein H. Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography. J Control Release. 2005;108:21–32.
Cui W, Bei J, Wang S, Zhi G, Zhao Y, Zhou X, et al. Preparation and evaluation of poly(L-lactide-co-glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography. J Biomed Mater Res B Appl Biomater. 2005;73:171–8.
El-Sherif DM, Wheatley MA. Development of a novel method for synthesis of a polymeric ultrasound contrast agent. J Biomed Mater Res A. 2003;66:347–55.
Quay S. Microbubble-based ultrasound contrast agents: the role of gas selection in microbubble persistence. J Ultrasound Med. 1994;13:S9.
Mattrey RF, Scheible FW, Gosink BB, Leopold GR, Long DM, Higgins CB. Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material. Radiology. 1982;145:759–62.
Ragde H, Kenny GM, Murphy GP, Landin K. Transrectal ultrasound microbubble contrast angiography of the prostate. Prostate. 1997;32:279–83.
Ge S, Giraud GG, Shiota T, Pantely GA, Xu J, Gong Z, et al. Microcirculatory flow dynamics during peripheral intravenous injection of echogentm: microscopic visualization of mesenteric microcirculatory flow with simultaneous transthoracic echo imaging in cats. J Am Coll Cardiol. 1995;25:227A.
Cotter B, Duong A, Raisinghani A, Keramati S, Mahmud E, Kwan OL, et al. Myocardial opacification by low doses EchoGen in patients: assessment of preactivation by closed syringe suction. J Am Coll Cardiol. 1996;27:126.
Nihoyannopoulos P, Rallidis L, Correas J-M, Quay SC. Myocardial enhancement following peripheral intravenous injection of activated QW3600 (EchoGen) in normal human volunteers. J Am Coll Cardiol. 1996;27:378.
Grayburn P. Perflenapent emulsion (EchoGen): a new long-acting phase-shift agent for contrast echocardiography. Clin Cardiol. 1997;20:I12–8.
Kornmann LM, Curfs DMJ, Hermeling E, van der Made I, de Winther MPJ, Reneman RS, et al. Perfluorohexane-loaded macrophages as a novel ultrasound contrast agent: a feasibility study. Mol Imaging Biol. 2008;10:264–70.
Saha P, Modarai B, Humphries J, Mattock K, Waltham M, Burnand KG, et al. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol. 2009;9:109–18.
Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600–3.
Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752–6.
Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18:301–13.
Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med. 2002;8:563–71.
Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation. 1996;94:3334–40.
Lanza GM, Abendschein DR, Hall CS, Scott MJ, Scherrer DE, Houseman A, et al. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echocardiogr. 2000;13:608–14.
Winslow RM. Blood substitutes. Adv Drug Deliv Rev. 2000;40:131–42.
Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Temperature dependence of ultrasonic enhancement with a site-targeted contrast agent. J Acoust Soc Am. 2001;110:1677–84.
Marsh JN, Hall CS, Wickline SA, Lanza GM. Temperature dependence of acoustic impedance for specific fluorocarbon liquids. J Acoust Soc Am. 2002;112:2858–62.
Marsh JN, Hall CS, Scott MJ, Fuhrhop RW, Gaffney PJ, Wickline SA, et al. Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. IEEE Trans Ultrason Ferroelectr Freq Control. 2002;49:29–38.
Marsh JN, Partlow KC, Abendschein DR, Scott MJ, Lanza GM, Wickline SA. Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med Biol. 2007;33:950–8.
Hughes MS, Marsh JN, Zhang H, Woodson AK, Allen JS, Lacy EK, et al. Characterization of digital waveforms using thermodynamic analogs: Detection of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Control. 2006;53:1609–16.
Hughes MS, McCarthy JE, Marsh JN, Arbeit JM, Neumann RG, Fuhrhop RW, et al. Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging. J Acoust Soc Am. 2007;121:3542–57.
Hughes MS, Marsh JN, Arbeit JM, Neumann RG, Fuhrhop RW, Wallace KD, et al. Application of Renyi entropy for ultrasonic molecular imaging. J Acoust Soc Am. 2009;125:3141–5.
Couture O, Bevan PD, Cherin E, Cheung K, Burns PN, Foster FS. Investigating perfluorohexane particles with high-frequency ultrasound. Ultrasound Med Biol. 2006;32:73–82.
Couture O, Bevan PD, Cherin E, Cheung K, Burns PN, Foster FS. A model for reflectivity enhancement due to surface bound submicrometer particles. Ultrasound Med Biol. 2006;32:1247–55.
El-Sherif DM, Lathia JD, Le NT, Wheatley MA. Ultrasound degradation of novel polymer contrast agents. J Biomed Mater Res A. 2004;68:71–8.
Pisani E, Tsapis N, Paris J, Nicolas V, Cattel L, Fattal E. Polymeric nano/microcapsules of liquid perfluorocarbons for ultrasonic imaging: physical characterization. Langmuir. 2006;22:4397–402.
Pisani E, Tsapis N, Galaz B, Santin M, Berti R, Taulier N, et al. Perfluorooctyl bromide polymeric capsules as dual contrast agents for ultrasonography and magnetic resonance imaging. Adv Funct Mater. 2008;18:2963–71.
Pisani E, Fattal E, Paris J, Ringard C, Rosilio V, Tsapis N. Surfactant dependent morphology of polymeric capsules of perfluorooctyl bromide: Influence of polymer adsorption at the dichloromethane-water interface. J Colloid Interface Sci. 2008;326:66–71.
Reed AM, Gilding DK. Biodegradable polymers for use in surgery—poly(glycolic)/poly(Iactic acid) homo and copolymers: 2. In vitro degradation. Polymer. 1981;22:494–8.
Yamaguchiand K, Anderson JM. Invivo biocompatibility studies of medisorb(R) 65/35 D. L-lactide glycolide copolymer microspheres. J Control Release. 1993;24:81–93.
Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93–102.
Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214–21.
Diaz-Lopez R, Tsapis N, Libong D, Chaminade P, Connan C, Chehimi MM, et al. Phospholipid decoration of microcapsules containing perfluorooctyl bromide used as ultrasound contrast agents. Biomaterials. 2009;30:1462–72.
Fang JY, Hung CF, Hua SC, Hwang TL. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells. Ultrasonics. 2009;49:39–46.
Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst. 2007;99:1095–106.
Gao Z, Kennedy AM, Christensen DA, Rapoport NY. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics. 2008;48:260–70.
Maeda H. The enhanced permeability and Retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advan Enzyme Regul. 2001;41:189–207.
Uchegbu I. Parenteral drug delivery: 1. Pharm J. 1999;263:309–18.
Waters EA, Wickline SA. Contrast agents for MRI. Basic Res Cardiol. 2008;103:114–21.
McKieand S, Brittenden J. (ii) Basic science: magnetic resonance imaging. Curr Orthop. 2005;19:13–9.
Yan G-P, Robinson L, Hogg P. Magnetic resonance imaging contrast agents: overview and perspectives. Radiography. 2007;13:e5–19.
Hengererand A, Grimm J. Molecular magnetic resonance imaging. Biomed Imaging Intervention J. 2006;2:e8.
Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ, et al. In vitro demonstration using F-19 magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol. 2006;41:305–12.
Holland GN, Bottomley PA, Hinshaw WS. 19F magnetic resonance imaging. J Magn Reson. 1977;28:133–6.
Kimura A, Narazaki M, Kanazawa Y, Fujiwara H. 19F Magnetic resonance imaging of perfluorooctanoic acid encapsulated in liposome for biodistribution measurement. Magn Reson Imaging. 2004;22:855–60.
Schwarz R, Schuurmans M, Seelig J, Kunnecke B. 19F-MRI of perfluorononane as a novel contrast modality for gastrointestinal imaging. Magn Reson Med. 1999;41:80–6.
Mason RP, Nunnally RL, Antich PP. Tissue oxygenation: a novel determination using 19F surface coil NMR spectroscopy of sequestered perfluorocarbon emulsion. Magn Reson Med. 1991;18:71–9.
Clark LC Jr, Ackerman JL, Thomas SR, Millard RW, Hoffman RE, Pratt RG, et al. Perfluorinated organic liquids and emulsions as biocompatible NMR imaging agents for 19F and dissolved oxygen. Adv Exp Med Biol. 1984;180:835–45.
Mason RP, Shukla H, Antich PP. Oxygent(Tm)—a novel probe of tissue oxygen-tension. Biomaterials Artificial Cells and Immobilization Biotechnology. 1992;20:929–32.
Mason RP, Shukla H, Antich PP. In vivo oxygen-tension and temperature—simultaneous determination using f-19 nmr-spectroscopy of perfluorocarbon. Magn Reson Med. 1993;29:296–302.
Shukla HP, Mason RP, Storey C, Jeffrey FMH, Antich PP. The relationship of oxygen-tension and myocardial mechanical function—a F-19 Nmr-study. Circulation. 1992;86:693–3.
Shukla HP, Mason RP, Bansal N, Antich PP. Regional myocardial oxygen tension: F-19 MRI of sequestered perfluorocarbon. Magn Reson Med. 1996;35:827–33.
Shukla HP, Mason RP, Woessner DE, Antich PP. Comparison of 3 commercial perfluorocarbon emulsions as high-field F-19 Nmr probes of oxygen-tension and temperature. J Magn Reson B. 1995;106:131–41.
Thomas SR, Pratt RG, Millard RW, Samaratunga RC, Shiferaw Y, McGoron AJ, et al. In vivo PO2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field. Magn Reson Imaging. 1996;14:103–14.
Mason RP. Non-invasive physiology: 19F NMR of perfluorocarbons. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:1141–53.
Eidelberg D, Johnson G, Barnes D, Tofts PS, Delpy D, Plummer D, et al. 19F NMR imaging of blood oxygenation in the brain. Magn Reson Med. 1988;6:344–52.
Fishman JE, Joseph PM, Floyd TF, Mukherji B, Sloviter HA. Oxygen-sensitive 19F NMR imaging of the vascular system in vivo. Magn Reson Imaging. 1987;5:279–85.
Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, et al. Quantitative “magnetic resonance immunohistochemistry” with ligand-targeted (19)F nanoparticles. Magn Reson Med. 2004;52:1255–62.
Winter P, Athey P, Kiefer G, Gulyas G, Frank K, Fuhrhop R, et al. Improved paramagnetic chelate for molecular imaging with MRI. Proceedings of the Fifth International Conference on Scientific and Clinical Apllications of Magnetic Carriers. J Magn Magn Mater. 2005;293:540–5.
Neubauer AM, Sim H, Winter PM, Caruthers SD, Williams TA, Robertson JD, et al. Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med. 2008;60:1353–61.
Neubauer AM, Caruthers SD, Hockett FD, Cyrus T, Robertson JD, Allen JS, et al. Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J Cardiovasc Magn Reson. 2007;9:565–73.
Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. Faseb J. 2007;21:1647–54.
Ruiz-Cabello J, Walczak P, Kedziorek DA, Chacko VP, Schmieder AH, Wickline SA, et al. In vivo “hot spot” MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med. 2008;60:1506–11.
Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, et al. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. Faseb J. 2008;22:4179–89.
Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson. 2008;10:43.
Ahrens ET, Flores R, Xu HY, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23:983–7.
Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med. 2007;58:725–34.
Janjic JM, Srinivas M, Kadayakkara DKK, Ahrens ET. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc. 2008;130:2832–41.
Flogel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008;118:140–8.
Webb AG, Wong M, Kolbeck KJ, Magin R, Suslick KS. Sonochemically produced fluorocarbon microspheres: a new class of magnetic resonance imaging agent. J Magn Reson Imaging. 1996;6:675–83.
Nystrom AM, Bartels JW, Du W, Wooley KL. Perfluorocarbon-loaded shell crosslinked knedel-like nanoparticles: lessons regarding polymer mobility and self-assembly. J Polym Sci A-Polym Chem. 2009;47:1023–37.
Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng. 2009.
Acknowledgments
Authors acknowledge financial support from CONACYT, Agence Nationale de la Recherche (ANR ACUVA NT05-3-42548) and Fondation de l’Avenir. Authors would like to thank S. L. Bridal, M. Santin and O. Lucidarme for fruitful discussions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Díaz-López, R., Tsapis, N. & Fattal, E. Liquid Perfluorocarbons as Contrast Agents for Ultrasonography and 19F-MRI. Pharm Res 27, 1–16 (2010). https://doi.org/10.1007/s11095-009-0001-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-009-0001-5